Thông tin thuốc gốc
Chỉ định và Liều dùng
Adult: As part of a mulitdrug regimen: For standard unsupervised 2-mth treatment: <50 kg: 1.5 g daily; ≥50 kg: 2 g daily. For intermittent supervised 2-mth treatment: <50 kg: 2 g 3 times wkly; ≥50 kg: 2.5 g 3 times wkly.
Child: As part of a mulitdrug regimen: For standard unsupervised 2-mth treatment: 35 mg/kg daily. For intermittent supervised 2-mth treatment: 50 mg/kg 3 times wkly.
Suy thận
May need dose reduction.
Suy gan
Severe: Contraindicated.
Cách dùng
Should be taken with food.
Chống chỉ định
Hypersensitivity. Hyperuricaemia and/or gouty arthritis, acute porphyria. Severe hepatic impairment.
Thận trọng
Patient w/ DM, history of gout. Mild to moderate hepatic and renal impairment. Pregnancy and lactation.
Tác dụng không mong muốn
Hyperuricaemia, leading to acute gout; anorexia, nausea, vomiting, aggravation of peptic ulcer, arthralgia, malaise, fever, sideroblastic anaemia, thrombocytopenia, dysuria. Rarely, photosensitivity, pellagra, rash.
Potentially Fatal: Hepatotoxicity.
Chỉ số theo dõi
Monitor liver function, serum uric acid, sputum culture; chest x-ray 2-3 mth into treatment and at completion.
Quá liều
Symptoms: Liver toxicity and hyperuricaemia. Management: Empty the stomach by gastric lavage if necessary. Employ general supportive measures. May give benzodiazepine if there is evidence of CNS stimulation and probenecid for hyperuricaemia.
Tương tác
Antagonises the effect of uricosuric agents (e.g. probenecid, sulfinpyrazone). May reduce the contraceptive effect of oestrogens. May inactivate oral typhoid vaccine. May increase the serum concentration of ciclosporin. May enhance the hepatotoxic effect of rifampicin.
Ảnh hưởng đến kết quả xét nghiệm
May interfere w/ Acetest® and Ketostix® urine tests to produce pinkish-brown color.
Tác dụng
Mechanism of Action: Pyrazinamide may be bacteriostatic or bactericidal in action, depending on the concentration of the drug attained at the site of the infection and the susceptibility of the infecting organism. Its activity appears to partly depend on conversion of the drug to pyrazinoic acid (POA), which lowers the pH of the environment below that which is necessary for growth of Mycobacterium tuberculosis. Susceptible strains of M. tuberculosis produce pyrazinamidase, an enzyme that deaminates pyrazinamide to POA, and the in vitro susceptibility of a given strain of the organism appears to correspond to its pyrazinamidase activity.
Absorption: Readily absorbed from the GI tract. Time to peak plasma concentration: Approx 2 hr.
Distribution: Widely distributed in body fluids and tissues, diffuses in the CSF and enters breast milk. Plasma protein binding: 50%.
Metabolism: Undergoes hepatic metabolism via hydrolysis to pyrazinoic acid (major active metabolite) and subsequently hydroxylated to 5-hydroxypyrazinoic acid (major excretory product).
Excretion: Via urine by glomerular filtration (approx 70% mainly as metabolites, approx 4% as unchanged drug). Half-life: Approx 9-10 hr.
Đặc tính

Chemical Structure Image

Source: National Center for Biotechnology Information. PubChem Database. Pyrazinamide, CID=1046, (accessed on Jan. 22, 2020)

Bảo quản
Store between 15-30°C.
Phân loại MIMS
Thuốc kháng lao
Tài liệu tham khảo
Anon. Pyrazinamide. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. Accessed 26/08/2014.

Buckingham R (ed). Pyrazinamide. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. Accessed 26/08/2014.

McEvoy GK, Snow EK, Miller J et al (eds). Pyrazinamide. AHFS Drug Information (AHFS DI) [online]. American Society of Health-System Pharmacists (ASHP). Accessed 26/08/2014.

Pyrazinamide Tablet (DAVA Pharmaceuticals, Inc). DailyMed. Source: U.S. National Library of Medicine. Accessed 26/08/2014.

Thông báo miễn trừ trách nhiệm: Thông tin này được MIMS biên soạn một cách độc lập dựa trên thông tin của Pyrazinamide từ nhiều nguồn tài liệu tham khảo và được cung cấp chỉ cho mục đích tham khảo. Việc sử dụng điều trị và thông tin kê toa có thể khác nhau giữa các quốc gia. Vui lòng tham khảo thông tin sản phẩm trong MIMS để biết thông tin kê toa cụ thể đã qua phê duyệt ở quốc gia đó. Mặc dù đã rất nỗ lực để đảm bảo nội dung được chính xác nhưng MIMS sẽ không chịu trách nhiệm hoặc nghĩa vụ pháp lý cho bất kỳ yêu cầu bồi thường hay thiệt hại nào phát sinh do việc sử dụng hoặc sử dụng sai các thông tin ở đây, về nội dung thông tin hoặc về sự thiếu sót thông tin, hoặc về thông tin khác. © 2024 MIMS. Bản quyền thuộc về MIMS. Phát triển bởi
  • LykaLynamide
  • Prazide
  • Pyraxel
  • Pyrazinamide Cadila
  • Pyrazynamid Yuhan
  • Pyzina
  • PZA Sandoz-Imexpharm
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in